Hot New Beverage Concepts for 2013: Episode Two
Adomas Pranevicius, CEO of MyDrink Beverages, gives BeverageDaily.com readers the further lowdown on new non-alcoholic drinks concepts that could set the market alight in 2013.
Adomas Pranevicius, CEO of MyDrink Beverages, gives BeverageDaily.com readers the further lowdown on new non-alcoholic drinks concepts that could set the market alight in 2013.
The Food and Drug Administration (FDA) has told US Senators Dick Durbin and Richard Blumenthal that is reviewing the safety of energy drinks and may take regulatory action if it finds a health risk.
Belgian supplier Beneo’s dessert thinktank is showing off some product concepts using sugar-free, ‘tooth-friendly’ isomalt and an already launched oligofructose-stevia blends for functional fibre candy.
Exposing healthy people to modified pathogens in a controlled clinical trial setting could be an exciting new way for industry to overcome the challenges of health claim substantiation, says Nizo Food Research expert.
The evidence supporting the heart health benefits of omega-3 fatty acids is strong, despite ‘less conclusive’ recent studies, says a new review from the Linus Pauling Institute at Oregon State University.
USANA Health Sciences has taken a conservative approach to new product development, making it a company lean on products but long on trust, says Brian Dixon, PhD, executive director of new product development.
Register now for free access to today's first ever online event devoted to Operational Efficiency in food and beverage processing, organized by FoodProductionDaily.com and William Reed Business Media.
Netherlands based manufacturer of gelatine and collagen peptides says it wants to expand further into the skin care category on the back of new clinical trials as well as expanding its production into Brazil.
A strike at the ports of Los Angeles and Long Beach is interrupting shipments of raw materials and is creating a “fulfillment panic” in the herbal industry, according to a leading botanical supplier.
Swiss biotech firm Evolva has bought failing Fluxome’s, yeast-derived resveratrol business for about €550,000 in cash and shares, but says it has no interest in the remaining omega-3 business being sold by sealed auction.